Dr William Wang, Director and Site head of Asia Pacific Hub, Department of Biostatistics and Research Decision Sciences (BARDS), Merck, China shares with us his insights on innovative quantitative sciences at Biopharma Asia Convention 2011:
Dr Wang has over 16 years of experience in the pharmaceutical industry in the United States, with expertise in statistical design/analysis, scientific programming and clinical data management. He has worked for Fox Chase Cancer Center, Astra Merck, Covance and Merck Co & Inc. During his 11-year tenure at Merck, he has led the statistical supports for major regulatory filings of drug/vaccine products, which won him Merck’s key innovator award (2005). He has been active in statistical researches, with more than 40 statistical publications/presentations. He was assigned to establish the BARDS China operations in late 2007.
Key issues that Dr Wang discussed were:
1. Utilising adaptive design methodologies to increase efficiency in clinical drug development
2. Establishing a suitable biomarker for efficacy or safety evaluation
3. Applying simulation and modelling throughout various developmental stages to forecast clinical requirements
To learn more, click here to download the slides now!